Hawthorn berry/leaf/flower extract is one of the most evidence-backed cardiovascular herbs, with German Commission E approval and over 30 clinical trials for heart failure (NYHA class I-III). The SPICE trial (2,681 patients) was the largest — while it missed its primary endpoint (all-cause mortality), it showed a 39.7% reduction in sudden cardiac death in a pre-specified subgroup. Our research shows hawthorn has genuine positive inotropic (strengthens heart contraction), vasodilatory, and antiarrhythmic properties. WS 1442 (Crataegutt®) is the standardized extract used in nearly all positive trials.
Hawthorn's OPCs (oligomeric procyanidins) and vitexin-2''-O-rhamnoside work through: (1) PDE3 inhibition in cardiac myocytes — increases cAMP → stronger cardiac contraction (positive inotropy) without proarrhythmic risk; (2) eNOS activation — increases coronary and peripheral NO → vasodilation; (3) ACE inhibition (mild) — reduces angiotensin II → decreases afterload; (4) antiarrhythmic — extends the refractory period of cardiac action potentials, reducing premature beats; (5) antioxidant — protects cardiac tissue from ischemia-reperfusion injury via ROS scavenging. The PDE3 mechanism is pharmacologically similar to milrinone (prescription heart failure drug) but much milder.
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.